Atazanavir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?

被引：3
|
作者：
Hill, A [1 ]
机构：
[1] Univ Liverpool, Dept Pharmacol, Liverpool L69 3BX, Merseyside, England
来源：
AIDS | 2005年 / 19卷 / 17期
关键词：
D O I：
10.1097/01.aids.0000194137.73876.d5
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页码：2054 / 2055
页数：2
相关论文
共 50 条
  • [1] Response to 'Atazanvir/ritonavir versus lopinavir/ritonavir: equivalent or different efficacy profiles?' by Hill
    Johnson, Margaret
    AIDS, 2006, 20 (15) : 1987 - 1987
  • [2] Electrocardiogram Abnormalities with Atazanavir and Lopinavir/Ritonavir
    Rathbun, R. Chris
    Liedtke, Michelle D.
    Blevins, Steve M.
    Harrison, Donald
    Lockhart, Staci M.
    Salvaggio, Michelle
    Acosta, Edward P.
    HIV CLINICAL TRIALS, 2009, 10 (05): : 328 - 336
  • [3] Efficacy and Safety of Atazanavir/Ritonavir Versus Lopinavir/Ritonavir in Hospitalized COVID-19 Patients: A Randomized Clinical Trial
    Siami, Zeinab
    Dehghan, Danial
    Khavandegar, Armin
    Lak, Mehran
    Bakhtiyari, Mahmood
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2022, 24 (05)
  • [4] Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity
    Caumo, Andrea
    Guffanti, Monica
    Perseghin, Gianiuca
    Galli, Laura
    Lazzarin, Adriano
    Luzi, Livio
    Castagna, Antonella
    AIDS, 2007, 21 (17) : 2366 - 2367
  • [5] Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
    Squires, Kathleen E.
    Johnson, Margaret
    Yang, Rong
    Uy, Jonathan
    Sheppard, Louise
    Absalon, Judith
    McGrath, Donnie
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2011, 66 (02) : 363 - 370
  • [6] The outcome of switching from ritonavir boosted lopinavir to ritonavir boosted atazanavir or darunavir
    Rockwood, N.
    Singh, G. Jagjit
    Mandhalia, S.
    Nelson, M.
    HIV MEDICINE, 2012, 13 : 75 - 75
  • [7] Efficacy and tolerability of tenofovir-containing regimens in combination with either lopinavir/ritonavir or atazanavir/ritonavir in a veteran population
    Lee, L.
    Fung, H. B.
    Bandres, J. C.
    ANTIVIRAL THERAPY, 2009, 14 (07) : A50 - A50
  • [8] Efficacy and safety of switching suppressed patients with elevated triglycerides from lopinavir/ritonavir or fosamprenavir/ritonavir to atazanavir/ritonavir or darunavir/ritonavir based therapy: The LARD study
    Skiest, Daniel J.
    Cohen, Calvin
    Khanlou, Homayoon
    DeJesus, Edwin
    Vanig, Thanes
    Tribble, Marc
    Petroll, Andrew
    Olivet, Hannah
    Mounzer, Karam
    Corales, Robert
    Rhame, Frank
    Bellos, Nicholaos
    Garb, Jane
    HIV & AIDS REVIEW, 2012, 11 (04): : 77 - 83
  • [9] Lower atovaquone/proguanil concentrations in patients taking efavirenz, lopinavir/ritonavir or atazanavir/ritonavir
    Van Luin, Matthijs
    Van der Ende, Marchina E.
    Richter, Clemens
    Visser, Mirjam
    Faraj, Diari
    Van der Ven, Andre
    Gelinck, Luc
    Kroon, Frank
    Wit, Ferdinand W.
    Van Schaik, Ron H. N.
    Kuks, Paul F. M.
    Burger, David M.
    AIDS, 2010, 24 (08) : 1223 - 1226
  • [10] Atazanavir plus ritonavir or saquinavir, and lopinavir/ritonavir in patients experiencing multiple virological failures
    Johnson, M
    Grinsztejn, B
    Rodriguez, C
    Coco, J
    DeJesus, E
    Lazzarin, A
    Lichtenstein, K
    Rightmire, A
    Sankoh, S
    Wilber, R
    AIDS, 2005, 19 (02) : 153 - 162
12345